A single-centre, randomised, double-blind, vehicle-controlled, proof-of-concept study of glycopyrrolate in the treatment of primary axillary hyperhidrosis

Stiefel Laboratories0 个研究点目标入组 36 人开始时间: 2007年11月9日最近更新: 2020年1月13日

试验速览

暂无简介。

•1. 16 years of age or older
•2. Diagnosis of primary, axilliary hyperhidrosis of at least 6 months duration
•3. Ability and willingness to follow all study procedurs, attend all scheduled visits, and successfully complete the study
•4. Sign a written informed consent form

•1. Intravenous (IV) or oral glycopyrrolate treatment within 8 weeks prior to study enrollment.
•2. Prior axillary use of non prescription/ over-the-counter (OTC antiperspirants containing aluminum chloride (or other metallic salts) within 24 hours of study enrollment.
•3. Prior axillary use of prescription antiperspirants containing aluminum chloride (or other metallic salts) within the 4 weeks.
•4. Known history of a condition that may cause secondary hyperhidrosis.
•5. Known history of a condition that could be exacerbated by the use of anticholinergics.
•6. Active infection of the axillae.
•7. Prior treatment with botulinum toxin (eg, Botox®) for axillary hyperhidrosis within 1 year.
•8. Prior treatment with iontophoresis within 4 weeks.
•9. Prior surgical procedure for hyperhidrosis.
•10. Treatment with psychotherapeutic agents within the 8 weeks.
•11. Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 8 weeks.
•12. Abnormal blood pressure.
•13. Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.

发起方

Stiefel Laboratories